Carrie K Jones Selected Research

Catalepsy

10/2019	Discovery, Structure-Activity Relationship, and Biological Characterization of a Novel Series of 6-((1 H-Pyrazolo[4,3- b]pyridin-3-yl)amino)-benzo[ d]isothiazole-3-carboxamides as Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 4 (mGlu4).
1/2016	Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.
1/2016	Discovery of 3-aminopicolinamides as metabotropic glutamate receptor subtype 4 (mGlu4) positive allosteric modulator warheads engendering CNS exposure and in vivo efficacy.
8/2015	Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.
12/2014	Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM).
3/2013	The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease.
3/2012	Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease.
2/2012	The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
12/2011	The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease.
11/2011	Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carrie K Jones Research Topics

Disease

34	Schizophrenia (Dementia Praecox) 11/2020 - 03/2005
13	Parkinson Disease (Parkinson's Disease) 10/2019 - 08/2009
12	Catalepsy 10/2019 - 10/2008
11	Alzheimer Disease (Alzheimer's Disease) 12/2020 - 10/2008
9	Pain (Aches) 05/2019 - 09/2001
7	Hyperalgesia 02/2007 - 09/2001
4	Neurobehavioral Manifestations 01/2019 - 05/2010
3	Cognitive Dysfunction 01/2021 - 03/2005
3	Psychotic Disorders (Schizoaffective Disorder) 03/2015 - 06/2014
2	Opioid-Related Disorders (Opiate Addiction) 01/2022 - 01/2019
2	Substance-Related Disorders (Drug Abuse) 01/2019 - 03/2016
2	Rett Syndrome (Rett's Disorder) 01/2018 - 01/2017
2	Cocaine-Related Disorders (Cocaine Addiction) 03/2016 - 08/2013
2	Dyskinesias (Dyskinesia) 01/2016 - 08/2015
2	Autistic Disorder (Autism) 01/2016 - 09/2012
2	Fragile X Syndrome (Martin Bell Syndrome) 01/2016 - 09/2012
2	Seizures (Absence Seizure) 09/2013 - 08/2009
2	Central Nervous System Diseases (CNS Diseases) 09/2013 - 10/2008
2	Acute Pain 02/2005 - 09/2001
1	Alcoholism (Alcohol Abuse) 12/2020
1	Neurodegenerative Diseases (Neurodegenerative Disease) 12/2020
1	Neurodevelopmental Disorders 01/2017
1	Syndrome (Syndromes) 01/2017
1	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 03/2015
1	Brain Diseases (Brain Disorder) 02/2015
1	Infections 09/2014
1	Human Influenza (Influenza) 09/2014
1	Communicable Diseases (Infectious Diseases) 08/2013

Drug/Important Bio-Agent (IBA)

20	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 01/2022 - 09/2001
14	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA 01/2016 - 01/2005
11	Haloperidol (Haldol)FDA LinkGeneric 10/2019 - 11/2008
7	Cholinergic Agents (Cholinergics)IBA 12/2020 - 03/2005
7	CarrageenanIBA 02/2007 - 09/2001
5	Antipsychotic Agents (Antipsychotics)IBA 01/2019 - 10/2008
5	Pharmaceutical PreparationsIBA 01/2018 - 02/2007
5	Capsaicin (Zostrix)FDA Link 10/2006 - 09/2001
4	Glutamate Receptors (Glutamate Receptor)IBA 12/2016 - 11/2012
4	Metabotropic Glutamate 5 ReceptorIBA 03/2016 - 12/2013
4	Muscarinic AgonistsIBA 01/2012 - 09/2001
3	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2021 - 11/2012
3	Acetylcholine (Acetylcholine Chloride)FDA Link 12/2020 - 01/2012
3	Analgesics (Analgesic Drugs)IBA 05/2019 - 01/2005
3	Morphine (MS Contin)FDA LinkGeneric 05/2019 - 02/2005
3	N-Methylaspartate (NMDA)IBA 12/2016 - 05/2015
3	metabotropic glutamate receptor 4IBA 01/2016 - 08/2015
3	Levodopa (L Dopa)FDA LinkGeneric 01/2016 - 02/2012
3	Glutamic Acid (Glutamate)FDA Link 08/2015 - 11/2012
3	Reserpine (Serpasil)FDA Link 03/2013 - 11/2008
3	metabotropic glutamate receptor 2IBA 01/2009 - 01/2005
3	Duloxetine Hydrochloride (Cymbalta)FDA Link 02/2007 - 02/2005
3	Formaldehyde (Formol)FDA Link 06/2005 - 09/2001
2	Muscarinic M4 ReceptorIBA 12/2020 - 01/2018
2	VU0466551IBA 05/2019 - 01/2019
2	Opioid Analgesics (Opioids)IBA 01/2019 - 01/2019
2	Dizocilpine Maleate (Dizocilpine)IBA 01/2018 - 03/2016
2	xanomelineIBA 01/2017 - 05/2010
2	N-(3-chlorophenyl)picolinamideIBA 08/2015 - 02/2012
2	Neurotransmitter Agents (Neurotransmitter)IBA 03/2015 - 12/2012
2	Amphetamine (Amfetamine)FDA LinkGeneric 03/2015 - 07/2014
2	ProdrugsIBA 12/2013 - 06/2005
2	Cholinergic ReceptorsIBA 12/2012 - 01/2012
2	N- (3- oxo- 3- (4- (pyridin- 4- yl)piperazin- 1- yl)propyl)benzo(c)(1,2,5)thiadiazole- 4- sulfonamideIBA 03/2012 - 08/2009
2	Scopolamine (Hyoscine)FDA Link 03/2012 - 09/2001
2	metabotropic glutamate receptor 3 (mGluR3)IBA 01/2009 - 07/2006
2	Acetic Acid (Vinegar)FDA LinkGeneric 02/2007 - 02/2005
2	Ibuprofen (Motrin)FDA LinkGeneric 02/2007 - 02/2005
1	VU6019650IBA 01/2022
1	VU0652957IBA 03/2019
1	Opioid Receptors (Opioid Receptor)IBA 01/2019
1	RNA (Ribonucleic Acid)IBA 01/2018
1	VU0467485IBA 02/2017
1	LigandsIBA 01/2017
1	Methyl-CpG-Binding Protein 2IBA 01/2017
1	VU0476406IBA 01/2017
1	Hypnotics and Sedatives (Sedatives)IBA 03/2016
1	Clozapine (Clozaril)FDA LinkGeneric 03/2016
1	5- amino- 3,4- dimethyl- N- (4- ((trifluoromethyl)sulfonyl)benzyl)thieno(2,3- c)pyridazine- 6- carboxamideIBA 03/2016
1	Proteins (Proteins, Gene)FDA Link 01/2016
1	Therapeutic UsesIBA 01/2016
1	gamma-Aminobutyric Acid (GABA)IBA 08/2015
1	Dihydroxyphenylalanine (Dopa)IBA 08/2015
1	LSP1 2111IBA 08/2015
1	VU0409551IBA 06/2015
1	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 03/2015
1	Neuropeptide YIBA 03/2015
1	Serotonin (5 Hydroxytryptamine)IBA 03/2015
1	Exenatide (Byetta)FDA Link 12/2014
1	Phospholipase DIBA 09/2014
1	1-dodecylpyridoxal (PLD)IBA 09/2014
1	Cytochrome P-450 CYP3AIBA 12/2013
1	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 09/2013
1	Cocaine (Cocaine HCl)IBA 08/2013
1	VU0463841IBA 08/2013
1	metabotropic glutamate receptor 8IBA 03/2013
1	SaltsIBA 03/2013
1	benzocycloheptapyridineIBA 01/2013
1	ML253IBA 01/2013

Therapy/Procedure

2	Therapeutics 08/2013 - 12/2012
1	Drug Therapy (Chemotherapy) 03/2016
1	Oral Administration 12/2013